Takeda Pharmaceutical
306 hedge funds and large institutions have $1.26B invested in Takeda Pharmaceutical in 2023 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 64 increasing their positions, 126 reducing their positions, and 51 closing their positions.
2,398% more call options, than puts
Call options by funds: $30.7M | Put options by funds: $1.23M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
2% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 51
1% more capital invested
Capital invested by funds: $1.24B → $1.26B (+$15.8M)
0.49% more ownership
Funds ownership: 5.08% → 5.58% (+0.49%)
2% less funds holding
Funds holding: 312 → 306 (-6)
49% less repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 126
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$63.3M |
| 2 |
MIP
Mondrian Investment Partners
London,
United Kingdom
|
+$58M |
| 3 |
Millennium Management
New York
|
+$38.7M |
| 4 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$13.8M |
| 5 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$19.4M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$18.6M |
| 3 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$12.7M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$8.03M |
| 5 |
Goldman Sachs
New York
|
-$7.76M |
TAK Hedge Fund Activity: Q4 2023 in Review
306 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q4 2023, worth a combined $1.26B — up 1.3% from $1.24B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new TAK positions and 51 closed out — a net gain of 1 holder — while 64 added to existing stakes and 126 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $63.3M. The largest seller was Bank of America, cutting an estimated $19.4M.
- 306 institutional investors held Takeda Pharmaceutical (TAK) as of Q4 2023, down from 312 in Q3 2023.
- Funds reported $1.26B of Takeda Pharmaceutical stock for Q4 2023, up 1.3% quarter-over-quarter.
- 52 funds opened new Takeda Pharmaceutical positions in Q4 2023 and 51 closed out, a net change of +1 holder.
- The largest Takeda Pharmaceutical buyer in Q4 2023 was Morgan Stanley, an estimated $63.3M added.
- The largest Takeda Pharmaceutical seller in Q4 2023 was Bank of America, an estimated $19.4M sold.
Based on aggregated 13F filings for Q4 2023.